Cancer during the COVID-19 pandemic: did we shout loudly enough and did anyone listen? A lasting legacy for nations
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
As the COVID-19 pandemic has ravaged the globe, the interdependence of nations' health and their economies has been brought into harsh focus. Governments are being advised by public health and infectious disease modellers and economists on trade-offs between economic effects of lockdowns and health services being overrun with cases of severe COVID-19. Economists are even putting a monetary value on COVID-19 vaccination speed and uptake strategies [1]. The article by Gheorghe et al. [2] in this edition provides a timely, well-sourced analysis quantitating and comparing both the health and economic cost of delays in diagnosis of cancer caused by the commencement of non-pharmaceutical interventions (NPIs) introduced in response to the COVID-19 pandemic in the UK. This makes for very uncomfortable reading.
European Journal of Cancer , éditorial, 2021